Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy

Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy

Background: Vedolizumab (VDZ) and infliximab are used to treat moderate to severe ulcerative colitis (UC). The choice of the drug to use at first-line is often based on a combination of clinical and economic factors. The cost of treatment pathway is rarely considered. Therefore, this cost-consequenc...

Full description

Bibliographic Details
Main Authors: Patrizio Armeni, Elena Compagnucci, Gionata Fiorino, Vincenzo Lolli, Grazia Mazzone, Ambrogio Orlando, Mariabeatrice Principi, Roberto Ravasio, Fernando Rizzello, Edoardo Vincenzo Savarino, Francesca Tombari
Format: Article
Language:English
Published: AboutScience Srl 2024-03-01
Series:AboutOpen
Subjects:
Cost-Consequence Analysis
Inflammatory Bowel Disease
Infliximab
Ulcerative Colitis
Ulcerative Rectocolitis
Vedolizumab
Online Access:https://journals.aboutscience.eu/index.php/aboutopen/article/view/2893

Internet

https://journals.aboutscience.eu/index.php/aboutopen/article/view/2893

Similar Items